Comparative effectiveness of liraglutide in the treatment of type 2 diabetes

Mauro Rigato, Gian Paolo Fadini Department of Medicine, University Hospital of Padova, Padova, Italy Abstract: Type 2 diabetes is characterized by a progressive decline in beta cell function, with consequent worsening of glycemic control. The ideal antihyperglycemic treatment should achieve good a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rigato M, Fadini GP
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/10a69ac5cf7047d28ad81236f84c9c36
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:10a69ac5cf7047d28ad81236f84c9c36
record_format	dspace
spelling	oai:doaj.org-article:10a69ac5cf7047d28ad81236f84c9c362021-12-02T00:51:51ZComparative effectiveness of liraglutide in the treatment of type 2 diabetes1178-7007https://doaj.org/article/10a69ac5cf7047d28ad81236f84c9c362014-03-01T00:00:00Zhttp://www.dovepress.com/comparative-effectiveness-of-liraglutide-in-the-treatment-of-type-2-di-a16138https://doaj.org/toc/1178-7007 Mauro Rigato, Gian Paolo Fadini Department of Medicine, University Hospital of Padova, Padova, Italy Abstract: Type 2 diabetes is characterized by a progressive decline in beta cell function, with consequent worsening of glycemic control. The ideal antihyperglycemic treatment should achieve good and sustained glycemic control, with a low risk of hypoglycemia and no weight gain. This paper reviews the efficacy and tolerability of liraglutide, a glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes. Once-daily injection of liraglutide (at doses of 1.2 mg and 1.8 mg), as monotherapy or in combination with one or two oral antihyperglycemic agents, was associated with greater improvements in glycemic control compared with active comparators or placebo in several controlled, randomized Phase III trials, including the six trials of the LEAD (Liraglutide Effect and Action in Diabetes) program. Liraglutide also improved beta cell function, body weight, systolic blood pressure, and lipid profile, thereby achieving many of the goals of ideal antihyperglycemic therapy. Liraglutide was generally well tolerated in the Phase III trials. The most common adverse events were nausea, vomiting, and diarrhea, usually of mild to moderate intensity. The observed rate of pancreatitis was low and comparable with that of the general diabetic population. In conclusion, although most trials were relatively short and focused on surrogate endpoints, liraglutide emerges as an effective and well tolerated treatment for type 2 diabetes, carrying a low risk of hypoglycemia, weight loss, and possible reduction of cardiovascular risk. Keywords: body weight, hypoglycemia, cardiovascular, incretinRigato MFadini GPDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2014, Iss default, Pp 107-120 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Rigato M Fadini GP Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
description	Mauro Rigato, Gian Paolo Fadini Department of Medicine, University Hospital of Padova, Padova, Italy Abstract: Type 2 diabetes is characterized by a progressive decline in beta cell function, with consequent worsening of glycemic control. The ideal antihyperglycemic treatment should achieve good and sustained glycemic control, with a low risk of hypoglycemia and no weight gain. This paper reviews the efficacy and tolerability of liraglutide, a glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes. Once-daily injection of liraglutide (at doses of 1.2 mg and 1.8 mg), as monotherapy or in combination with one or two oral antihyperglycemic agents, was associated with greater improvements in glycemic control compared with active comparators or placebo in several controlled, randomized Phase III trials, including the six trials of the LEAD (Liraglutide Effect and Action in Diabetes) program. Liraglutide also improved beta cell function, body weight, systolic blood pressure, and lipid profile, thereby achieving many of the goals of ideal antihyperglycemic therapy. Liraglutide was generally well tolerated in the Phase III trials. The most common adverse events were nausea, vomiting, and diarrhea, usually of mild to moderate intensity. The observed rate of pancreatitis was low and comparable with that of the general diabetic population. In conclusion, although most trials were relatively short and focused on surrogate endpoints, liraglutide emerges as an effective and well tolerated treatment for type 2 diabetes, carrying a low risk of hypoglycemia, weight loss, and possible reduction of cardiovascular risk. Keywords: body weight, hypoglycemia, cardiovascular, incretin
format	article
author	Rigato M Fadini GP
author_facet	Rigato M Fadini GP
author_sort	Rigato M
title	Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
title_short	Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
title_full	Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
title_fullStr	Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
title_full_unstemmed	Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
title_sort	comparative effectiveness of liraglutide in the treatment of type 2 diabetes
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/10a69ac5cf7047d28ad81236f84c9c36
work_keys_str_mv	AT rigatom comparativeeffectivenessofliraglutideinthetreatmentoftype2diabetes AT fadinigp comparativeeffectivenessofliraglutideinthetreatmentoftype2diabetes
_version_	1718403419999305728

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes

Ejemplares similares